South Africa rolls out long-acting HIV prevention drug

South Africa has begun rolling out lenacapavir, a twice-yearly injection that significantly reduces HIV transmission risk, offering hope for future generations. The drug, administered in two injections, has shown over 99.9 percent effectiveness in preventing HIV. This innovative prevention method is being studied in an implementation trial involving 2,000 participants. South Africa has one of the world's highest HIV rates. Lenacapavir's long-acting nature is seen as a life-changing alternative to daily pills, with broader national rollout anticipated next year.